Literature DB >> 1562254

Argon laser trabeculoplasty controls one third of cases of progressive, uncontrolled, open angle glaucoma for 5 years.

G L Spaeth1, K A Baez.   

Abstract

Seventy-eight patients (109 eyes) with progressive glaucoma had argon laser trabeculoplasty as a substitute for filtration surgery and were then followed up for a minimum of 5 years. One hundred spots were placed at the anterior margin of the posterior trabecular meshwork over 360 degrees. Consecutive cases between 1980 and 1985 were reviewed, 95% of treated cases being included in the final analysis. Eighty-two eyes had primary open angle glaucoma. If only the group with primary open angle glaucoma is considered, the failure rate the first year was 19%. After that, the failure rate was approximately eight per year. At the end of 5 years, 65% of all eyes had failed. At the end of 10 years, data were available on 84 of the original 109 treated eyes; in 80 treatment had failed, and four were still receiving medical therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1562254     DOI: 10.1001/archopht.1992.01080160069032

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

1.  Membrane formation in the chamber angle after failure of argon laser trabeculoplasty: analysis of risk factors.

Authors:  T Koller; J Stürmer; C Remé; B Gloor
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

Review 2.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  [Current developments in minimally invasive glaucoma surgery].

Authors:  C Erb
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

4.  Risk factors for failures of trabeculectomies performed without antimetabolites.

Authors:  H Mietz; B Raschka; G K Krieglstein
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

5.  Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

Authors:  A L Robin; R Ritch; D Shin; B Smythe; T Mundorf; R P Lehmann
Journal:  Trans Am Ophthalmol Soc       Date:  1995

6.  In vivo femtosecond laser subsurface scleral treatment in rabbit eyes.

Authors:  Dongyul Chai; Gautam Chaudhary; Eric Mikula; Hui Sun; Ron Kurtz; Tibor Juhasz
Journal:  Lasers Surg Med       Date:  2010-09       Impact factor: 4.025

7.  Influence of argon laser trabeculoplasty on transforming growth factor-beta 2 concentration and bleb scarring following trabeculectomy.

Authors:  Iris Wimmer; Ulrich Welge-Luessen; Greda Picht; Franz Grehn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-07-25       Impact factor: 3.117

8.  Efficacy and safety of indomethacin 0.1% versus flurbiprofen 0.03% eyedrops in inflammation after argon laser trabeculoplasty. The Belgian Study Group on Glaucoma.

Authors:  M Goethals; L Missotten
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

Review 9.  Laser trabeculoplasty.

Authors:  R Coakes
Journal:  Br J Ophthalmol       Date:  1992-10       Impact factor: 4.638

10.  Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension.

Authors:  M G Uva; A Longo; M Reibaldi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-27       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.